Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
CorMedix Inc stock logo
CRMD
CorMedix
$13.61
+0.2%
$11.46
$3.61
$15.38
$923.10M1.621.24 million shs1.68 million shs
Nanobiotix S.A. Sponsored ADR stock logo
NBTX
Nanobiotix
$4.47
+4.2%
$3.89
$2.76
$6.00
$210.68M0.3615,753 shs2,954 shs
Organogenesis stock logo
ORGO
Organogenesis
$3.23
-1.2%
$3.68
$2.28
$6.71
$409.74M1.631.14 million shs1.49 million shs
Pharming Group N.V. Sponsored ADR stock logo
PHAR
Pharming Group
$10.60
-2.3%
$9.93
$6.65
$12.61
$710.92M0.026,093 shs1,340 shs
5G Stocks: The Path Forward is Profitable Cover

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
CorMedix Inc stock logo
CRMD
CorMedix
+0.22%-6.52%+10.74%+24.75%+214.32%
Nanobiotix S.A. Sponsored ADR stock logo
NBTX
Nanobiotix
+2.05%-13.20%+19.04%+23.48%-1.54%
Organogenesis stock logo
ORGO
Organogenesis
-1.22%+5.21%+7.31%-33.81%+30.77%
Pharming Group N.V. Sponsored ADR stock logo
PHAR
Pharming Group
-5.27%-2.49%+1.05%+19.05%+24.01%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
CorMedix Inc stock logo
CRMD
CorMedix
1.0758 of 5 stars
2.61.00.00.02.80.00.6
Nanobiotix S.A. Sponsored ADR stock logo
NBTX
Nanobiotix
2.1792 of 5 stars
3.35.00.00.01.10.00.6
Organogenesis stock logo
ORGO
Organogenesis
4.5807 of 5 stars
3.33.00.04.33.74.20.6
Pharming Group N.V. Sponsored ADR stock logo
PHAR
Pharming Group
2.3279 of 5 stars
3.53.00.00.02.90.00.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
CorMedix Inc stock logo
CRMD
CorMedix
3.17
Buy$15.8316.34% Upside
Nanobiotix S.A. Sponsored ADR stock logo
NBTX
Nanobiotix
2.50
Moderate Buy$8.0078.97% Upside
Organogenesis stock logo
ORGO
Organogenesis
2.50
Moderate Buy$5.5070.28% Upside
Pharming Group N.V. Sponsored ADR stock logo
PHAR
Pharming Group
3.00
Buy$30.00183.02% Upside

Current Analyst Ratings Breakdown

Latest NBTX, PHAR, ORGO, and CRMD Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/20/2025
CorMedix Inc stock logo
CRMD
CorMedix
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeOutperform ➝ Moderate Buy$13.00 ➝ $17.00
5/7/2025
CorMedix Inc stock logo
CRMD
CorMedix
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$12.00 ➝ $15.00
5/6/2025
CorMedix Inc stock logo
CRMD
CorMedix
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$15.00 ➝ $15.00
4/9/2025
CorMedix Inc stock logo
CRMD
CorMedix
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$12.00 ➝ $12.00
4/8/2025
CorMedix Inc stock logo
CRMD
CorMedix
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$15.00 ➝ $15.00
4/4/2025
Nanobiotix S.A. Sponsored ADR stock logo
NBTX
Nanobiotix
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$12.00 ➝ $8.00
3/26/2025
CorMedix Inc stock logo
CRMD
CorMedix
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform$12.00 ➝ $12.00
3/26/2025
CorMedix Inc stock logo
CRMD
CorMedix
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$18.00 ➝ $12.00
3/25/2025
CorMedix Inc stock logo
CRMD
CorMedix
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$15.00 ➝ $15.00
(Data available from 6/21/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
CorMedix Inc stock logo
CRMD
CorMedix
$43.47M21.23N/AN/A$1.40 per share9.72
Nanobiotix S.A. Sponsored ADR stock logo
NBTX
Nanobiotix
$39.18M5.38N/AN/A($1.51) per share-2.96
Organogenesis stock logo
ORGO
Organogenesis
$482.04M0.85$0.21 per share15.48$2.09 per share1.55
Pharming Group N.V. Sponsored ADR stock logo
PHAR
Pharming Group
$297.20M2.43$0.08 per share140.97$3.25 per share3.26
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
CorMedix Inc stock logo
CRMD
CorMedix
-$17.93M$0.2261.8714.48N/A20.81%22.57%17.02%8/13/2025 (Estimated)
Nanobiotix S.A. Sponsored ADR stock logo
NBTX
Nanobiotix
-$73.73MN/A0.00N/AN/AN/AN/AN/AN/A
Organogenesis stock logo
ORGO
Organogenesis
$860K-$0.17N/AN/AN/A-3.46%-4.00%-2.26%8/6/2025 (Estimated)
Pharming Group N.V. Sponsored ADR stock logo
PHAR
Pharming Group
-$11.84M-$0.20N/A353.33N/A-4.14%-6.01%-3.23%7/30/2025 (Estimated)

Latest NBTX, PHAR, ORGO, and CRMD Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/8/2025Q1 2025
Organogenesis stock logo
ORGO
Organogenesis
$0.04-$0.13-$0.17-$0.17$90.77 million$86.69 million
5/8/2025Q1 2025
Pharming Group N.V. Sponsored ADR stock logo
PHAR
Pharming Group
-$0.25-$0.22+$0.03-$0.22$67.74 million$79.09 million
5/6/2025Q1 2025
CorMedix Inc stock logo
CRMD
CorMedix
$0.25$0.30+$0.05$0.30$38.90 million$39.08 million
3/25/2025Q4 2024
CorMedix Inc stock logo
CRMD
CorMedix
$0.17$0.22+$0.05$0.22$27.46 million$30.00 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
CorMedix Inc stock logo
CRMD
CorMedix
N/AN/AN/AN/AN/A
Nanobiotix S.A. Sponsored ADR stock logo
NBTX
Nanobiotix
N/AN/AN/AN/AN/A
Organogenesis stock logo
ORGO
Organogenesis
N/AN/AN/AN/AN/A
Pharming Group N.V. Sponsored ADR stock logo
PHAR
Pharming Group
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
CorMedix Inc stock logo
CRMD
CorMedix
N/A
4.21
3.99
Nanobiotix S.A. Sponsored ADR stock logo
NBTX
Nanobiotix
N/A
1.04
1.04
Organogenesis stock logo
ORGO
Organogenesis
N/A
4.12
3.67
Pharming Group N.V. Sponsored ADR stock logo
PHAR
Pharming Group
0.39
2.76
2.00

Institutional Ownership

CompanyInstitutional Ownership
CorMedix Inc stock logo
CRMD
CorMedix
34.18%
Nanobiotix S.A. Sponsored ADR stock logo
NBTX
Nanobiotix
38.81%
Organogenesis stock logo
ORGO
Organogenesis
49.57%
Pharming Group N.V. Sponsored ADR stock logo
PHAR
Pharming Group
0.03%

Insider Ownership

CompanyInsider Ownership
CorMedix Inc stock logo
CRMD
CorMedix
5.30%
Nanobiotix S.A. Sponsored ADR stock logo
NBTX
Nanobiotix
3.45%
Organogenesis stock logo
ORGO
Organogenesis
33.00%
Pharming Group N.V. Sponsored ADR stock logo
PHAR
Pharming Group
2.07%
CompanyEmployeesShares OutstandingFree FloatOptionable
CorMedix Inc stock logo
CRMD
CorMedix
3067.82 million64.23 millionOptionable
Nanobiotix S.A. Sponsored ADR stock logo
NBTX
Nanobiotix
10047.13 million45.51 millionNot Optionable
Organogenesis stock logo
ORGO
Organogenesis
950126.85 million84.99 millionOptionable
Pharming Group N.V. Sponsored ADR stock logo
PHAR
Pharming Group
28068.03 million66.62 millionNot Optionable

Recent News About These Companies

European Penny Stocks Under €200M Market Cap To Watch

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
CorMedix stock logo

CorMedix NASDAQ:CRMD

$13.61 +0.03 (+0.22%)
Closing price 06/20/2025 04:00 PM Eastern
Extended Trading
$13.58 -0.02 (-0.18%)
As of 06/20/2025 07:17 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure. The company was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. CorMedix Inc. was incorporated in 2006 and is based in Berkeley Heights, New Jersey.

Nanobiotix stock logo

Nanobiotix NASDAQ:NBTX

$4.47 +0.18 (+4.20%)
Closing price 06/20/2025 03:57 PM Eastern
Extended Trading
$4.47 0.00 (0.00%)
As of 06/20/2025 05:40 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Nanobiotix S.A., a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. The company has a partnership with Lian Oncology Limited to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand. Nanobiotix S.A. was incorporated in 2003 and is headquartered in Paris, France.

Organogenesis stock logo

Organogenesis NASDAQ:ORGO

$3.23 -0.04 (-1.22%)
Closing price 06/20/2025 04:00 PM Eastern
Extended Trading
$3.28 +0.04 (+1.39%)
As of 06/20/2025 07:47 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Organogenesis Holdings Inc., a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Novachor, a chorion membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, cytokines, and growth factors; NuShield, dehydrated placental tissue covering amnion and chorion membranes for spongy/intermediate layer intact; and PuraPly AM, an antimicrobial barrier that enables conformability and fluid drainage. Its products also include FortiShield, a biosynthetic wound matrix for use as a temporary protective covering; PuraPly MZ, a micronized particulate version of PuraPly for the management of open wounds in the surgical setting; and CYGNUS Dual, a dehydrated placental tissue preserved to retain the ECM scaffold. The company's pipeline products include ReNu, a cryopreserved suspension used to support healing of soft tissues; PuraForce, a bioengineered porcine collagen surgical matrix for use in soft tissue reinforcement applications; and TransCyte, a bioengineered tissue for the treatment of partial thickness burns. It serves hospitals, wound care centers, government facilities, ambulatory service centers, and physician office through direct sales representives and independent agencies. Organogenesis Holdings Inc. was founded in 1985 and is headquartered in Canton, Massachusetts.

Pharming Group stock logo

Pharming Group NASDAQ:PHAR

$10.60 -0.25 (-2.30%)
Closing price 06/20/2025 03:58 PM Eastern
Extended Trading
$10.60 0.00 (0.00%)
As of 06/20/2025 05:16 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome. It also develops OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of HAE. The company has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105. Pharming Group N.V. was incorporated in 1988 and is headquartered in Leiden, the Netherlands.